首页 > 主讲嘉宾 > 详情
杨建新(CMO)
个人简介

拥有海外大型跨国药企、科研院所等机构逾25年的学术科研及生物制药研发的资深经验,涵盖从研究发现到临床开发阶段。发表论文30篇,拥有专利9项。

现任基石药业首席医学官;组建临床与注册团队,并领导超过八个肿瘤项目一期到三期的临床开发工作。

曾任百济临床开发负责人;组建百济神州临床团队,并领导四个肿瘤项目一期到关键试验阶段的临床开发工作,包括开发中国首个自主研发的抗PD-1单克隆抗体。

曾任美国科文斯肿瘤医学总监;曾任辉瑞肿瘤生物标记物资深首席科学家;曾任Tularik/Amgen公司研究科学家; 领导超过十个肿瘤项目的研究与开发。

拥有美国德州西南医学院博士学位,师从诺贝尔奖获得者Mike Brown博士和Joseph Goldstein博士;哈佛大学博士后,师从Stuart Schreiber博士;在南京医科大学和湖北医学院咸宁分院取得医学学位。



 A physician scientist and senior executive with 25+ year biomedical research and biopharmaceutical R&D experience in oncology, from discovery, translational medical to clinical development, with over 30 publications and 9 patents

 Serves as the funding CMO, built CStone clinical and RA team and lead the clinical development of over 8 oncology assets from Ph I to III

 Served as SVP and Head of Clinical Development at BeiGene, built BeiGene’s clinical team and led clinical development of 4 oncology assets from Ph I to pivotal trials including the first anti-PD-1 mAb originated in China

 Led research and development on over 10 oncology assets while serving as Oncology Medical Director in Covance(US), Senior Principle Scientist in cancer translational medicine in Pfizer(US) and Research Scientist in cancer genomics in Tularik/Amgen(US).

 PhD trained with Nobel laureates Drs. Mike Brown and Joseph Goldstein at UT Southwestern Med. Ctr.; Postdoctoral training with Dr. Stuart Schreiber at Harvard Univ.; MD from Hubei Medical College, Xianning and Nanjing Med. Univ.

发表论文